<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To study the expression status and clinical relevance of vascular endothelial growth factor-A (VEGF-A) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) tissues </plain></SENT>
<SENT sid="1" pm="."><plain>EXPERIMENTAL DESIGN: VEGF-A expression was investigated by immunohistochemistry in 89 cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Some demographic and histopathological variables were compared with VEGF-A expression to determine the prognostic significance in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: VEGF-A (-) was found in 24 cases; (+), (++) and (+++) stainings were detected in 24, 35 and six cases, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>VEGF-A (-) was found in 20 of 58 cases with left <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, while only four of 31 cases with right <z:hpo ids='HP_0003003'>colon cancer</z:hpo> were VEGF-A (-) (p=0.024) </plain></SENT>
<SENT sid="5" pm="."><plain>There was a trend for lower <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade and lesser serosal invasion in cases with VEGF-A (-) samples (p=0.07 and p=0.079, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>Although the correlation was not statistically significant, there was a trend for lower <z:hpo ids='HP_0011420'>death</z:hpo> rate in cases with VEGF-A (-) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> (p=0.087) </plain></SENT>
<SENT sid="7" pm="."><plain>The longest survival was found in cases with VEGF-A (-) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and the shortest survival was found in cases with VEGF-A (+++) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Median survival for patients with VEGF-A (-), (+), (++) and (+++) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> was 59, 47, 35 and 11 months, respectively (p=0.02) </plain></SENT>
<SENT sid="9" pm="."><plain>The Cox proportional hazards model identified stage IV disease and VEGF-A (+++) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> as having the most important influences upon overall survival (odds ratio: 5.1, 95% confidence interval: 2.0-13.0 and odds ratio: 3.6, 95% confidence interval: 1.0-12.7, respectively), followed by serosal invasion (odds ratio: 2.4, 95% confidence interval: 1.0-5.9) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: This study shows that VEGF-A is a poor prognostic factor in cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, but the relatively small size of the study group precluded the correlation with the entire known prognostic indicator </plain></SENT>
</text></document>